Trial reportBritish journal of clinical pharmacology2007
Effect of dronedarone on renal function in healthy subjects.
Trial report in British journal of clinical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 121 citations in OpenAlex.
- Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.European heart journal. Cardiovascular pharmacotherapy · 2022Trial
- Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.Clinical cardiology · 2022Trial
- Dronedarone in patients with congestive heart failure: insights from ATHENA.European heart journal · 2010Trial
- Identification of non-oncology drugs with activity against inflammatory and triple-negative breast cancer cell lines.Oncology letters · 2026Article
- Challenges of Serum Creatinine Level in GFR Assessment and Drug Dosing Decisions in Kidney Injury.Advanced pharmaceutical bulletin · 2024Review
- Ventricular arrhythmias in the context of chronic kidney disease and electrolyte imbalance.Herzschrittmachertherapie & Elektrophysiologie · 2024Review
- Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug-Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective.Clinical pharmacokinetics · 2024Review
- Renal Drug Transporters and Drug Interactions.Clinical pharmacokinetics · 2017Review
- The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature.BMC research notes · 2016Article
- Acute renal failure in patients treated with dronedarone or amiodarone: a large population-based cohort study in Italy.European journal of clinical pharmacology · 2015Article
- Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.Kidney international · 2014Article
- Dronedarone-associated acute renal failure: evidence coming from the Italian spontaneous ADR reporting database.British journal of clinical pharmacology · 2013Article
- Review
- Novel anti-arrhythmic medications in the treatment of atrial fibrillation.Current cardiology reviews · 2012Review
- Can we prevent or treat renal dysfunction in acute heart failure?Heart failure reviews · 2012Review
- Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.Clinical interventions in aging · 2012Review
- Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone.Patient related outcome measures · 2012Article
- Rationale and current perspective for early rhythm control therapy in atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2011Review
- Management of amiodarone-related thyroid problems.Therapeutic advances in endocrinology and metabolism · 2011Article
- Pharmacological management of atrial fibrillation: one, none, one hundred thousand.Cardiology research and practice · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess the effects of dronedarone on renal function and tubular cation handling.
methodsTwelve healthy males were enrolled in a randomized, cross-over, placebo-controlled, double-blind study. They received 400 mg dronedarone or placebo twice daily for 7 days. Baseline and on-treatment renal function tests were performed under strict standardization of intakes, by assessing creatinine, sinistrin, para-amino-hippurate (PAH) and N-methylnicotinamide (NMN) CLs, and electrolyte excretion.
resultsCompared with placebo, dronedarone significantly decreased renal creatinine CL (mean 138-119 ml min(-1) after dronedarone vs. 142-149 ml min(-1) after placebo) and NMN CL (448-368 ml min(-1)vs. 435-430 ml min(-1)), but did not alter renal sinistrin CL, PAH CL and other renal parameters.
conclusionsDronedarone reduces renal creatinine and NMN clearance by about 18%, without evidence of an effect on GFR, renal plasma flow or electrolyte exchanges. This suggests a specific partial inhibition of tubular organic cation transporters (OCT). A limited increase in serum creatinine is therefore expected with dronedarone treatment, but does not mean there is a decline in renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.